Reclast (Zoledronic Acid) Cost in Washington: 2026 Pricing, Insurance, and Savings Guide

What Reclast Actually Costs in Washington in 2026

The single biggest variable in what you pay for Reclast is whether you have insurance. The Novartis list price for brand-name Reclast hovers around $1,500 per infusion, a figure that reflects the wholesale acquisition cost before any rebates or negotiations 1. Generic zoledronic acid 5 mg/100 mL IV solution has pushed cash-pay prices down considerably. Across Washington retail and specialty pharmacies in 2026, the average out-of-pocket cash price lands near $600 for the drug itself.

That $600 figure does not include the infusion fee. Because zoledronic acid is administered intravenously over at least 15 minutes, you will also face a facility or administration charge. Hospital outpatient departments in Washington typically bill between $200 and $500 for the infusion visit under CPT code 96413 (chemotherapy/biologic infusion, first hour), though some facilities code it under 96365 (therapeutic IV infusion). The total out-of-pocket experience for an uninsured patient can therefore range from roughly $800 to $1,100 annually when combining the drug cost with the infusion fee.

Pricing varies by pharmacy and infusion site. A 2022 analysis published in the Journal of Bone and Mineral Research found that site-of-service differences accounted for up to a 3-fold variation in total zoledronic acid cost for the same patient population 2. Patients infused in physician offices paid significantly less than those treated in hospital outpatient settings.

Washington Medicaid Coverage for Reclast

Washington Apple Health (Medicaid) covers zoledronic acid for FDA-approved indications, but requires prior authorization. The PA process confirms an osteoporosis diagnosis (typically a DXA T-score of -2.5 or below at the hip or spine, or a history of fragility fracture) and may require documentation that the patient has tried or has contraindications to oral bisphosphonates like alendronate 3.

The Washington Health Care Authority's preferred drug list categorizes IV bisphosphonates as non-preferred agents, meaning your prescriber must submit clinical justification. Approval turnaround is usually 5 to 10 business days. Once approved, Medicaid covers both the drug and the infusion administration fee with zero or minimal copay for most beneficiaries.

Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research & Osteoporosis Center, has noted: "IV zoledronic acid is a particularly good option for patients who cannot tolerate oral bisphosphonates or who have adherence challenges, since a single yearly infusion eliminates daily or weekly pill burden" 4. This clinical rationale is exactly what Washington Medicaid reviewers look for in PA requests.

For dual-eligible patients (Medicare plus Medicaid), zoledronic acid is typically billed through Medicare Part B as a physician-administered drug under HCPCS code J3489. Medicaid then covers any remaining cost-sharing.

How Insurance Plans in Washington Handle Reclast

Most commercial insurers in Washington cover zoledronic acid, but the benefit structure matters. Reclast is a physician-administered injectable, so it is usually covered under your medical benefit (not the pharmacy benefit). This distinction affects your cost-sharing.

Under the medical benefit, you typically pay a percentage coinsurance rather than a flat copay. A plan with 20% coinsurance on the $1,500 list price would leave you owing $300 before any negotiated rate reductions. Plans that have negotiated generic zoledronic acid rates may bring your coinsurance down to $80 to $150. After meeting your annual out-of-pocket maximum, coverage reaches 100%.

Major Washington insurers and their general approach:

Premera Blue Cross and Regence BlueShield both cover generic zoledronic acid as a medical benefit with standard prior authorization. Specialty tier coverage may apply if billed through a specialty pharmacy.

Kaiser Permanente Washington administers zoledronic acid infusions at its own facilities, often resulting in lower total cost because both drug acquisition and infusion are handled internally.

Molina Healthcare and Coordinated Care, which serve Washington Medicaid managed-care enrollees, follow the Apple Health PA requirements and formulary guidelines.

The 2020 Endocrine Society Clinical Practice Guideline on osteoporosis management in postmenopausal women recommends bisphosphonates, including zoledronic acid, as first-line pharmacologic therapy for patients at high fracture risk 5. This guideline backing gives insurers little room to deny coverage when PA criteria are met.

The HORIZON-PFT Trial: Why Insurers Cover This Drug

Payers cover zoledronic acid because the evidence base is strong. The HORIZON Key Fracture Trial (HORIZON-PFT), published in the New England Journal of Medicine in 2007, randomized 7,765 postmenopausal women with osteoporosis to receive either zoledronic acid 5 mg IV annually or placebo over three years 3.

Results were definitive. Zoledronic acid reduced the risk of morphometric vertebral fractures by 70% (RR 0.30 to 95% CI 0.24 to 0.38) and hip fractures by 41% (HR 0.59 to 95% CI 0.42 to 0.83) compared to placebo 3. Non-vertebral fracture risk dropped by 25%. These reductions translated to a number needed to treat (NNT) of 14 for vertebral fractures and 91 for hip fractures over three years.

A companion trial, HORIZON-RFT, demonstrated a 28% reduction in clinical fractures and a 28% reduction in all-cause mortality among patients who had already sustained a hip fracture 6. The mortality finding was unexpected and remains one of the few instances where an osteoporosis drug has shown a survival benefit.

Dr. Dennis Black, lead investigator of HORIZON-PFT and professor of epidemiology at UCSF, stated at the time of publication: "Once-yearly infusion of zoledronic acid significantly reduced fractures at all sites, including the hip, which is the most devastating osteoporotic fracture" 3.

Compounded Zoledronic Acid in Washington: What Is and Is Not Available

Washington state permits licensed 503A compounding pharmacies to prepare medications for individual patients with valid prescriptions. Technically, a 503A pharmacy in Washington could compound zoledronic acid if it meets FDA and state board of pharmacy requirements for sterile compounding.

In practice, compounded zoledronic acid is uncommon. The drug is already available as an FDA-approved generic in a ready-to-infuse 5 mg/100 mL bag, which eliminates the clinical rationale for compounding in most cases. Compounding is typically reserved for situations where a commercially available product does not meet a specific patient need (such as an allergy to an inactive ingredient or a need for a non-standard concentration).

Washington's compounding regulations follow USP 797 and 800 standards for sterile preparations. Any 503A pharmacy compounding an IV product like zoledronic acid must maintain a cleanroom environment, conduct sterility and potency testing, and assign appropriate beyond-use dating 7. The Washington State Department of Health Pharmacy Quality Assurance Commission oversees compliance.

If you encounter a compounding pharmacy advertising zoledronic acid at a significantly lower price than the generic, verify that the pharmacy holds a current Washington state sterile compounding license and that the product has been tested for sterility and endotoxins. IV medications carry higher risk than oral compounds when quality is compromised.

Discount Programs and Savings Strategies for Washington Patients

Several pathways can reduce your zoledronic acid cost in Washington.

Generic substitution. Switching from brand-name Reclast to generic zoledronic acid is the single most effective cost reduction. The generic is therapeutically equivalent (FDA "AB" rated) and costs 40% to 60% less than the brand at most Washington pharmacies.

Novartis patient assistance. For uninsured or underinsured patients, Novartis offers a Patient Assistance Program (PAP) for brand-name Reclast. Eligibility typically requires household income below 400% of the federal poverty level and lack of prescription drug coverage. Application is through the Novartis Patient Assistance Foundation 8.

Manufacturer copay cards. Novartis has periodically offered copay savings cards for commercially insured patients, reducing out-of-pocket costs to as low as $0 for eligible individuals. These cards do not apply to government insurance (Medicare, Medicaid, Tricare). Availability changes annually, so confirm current offers directly with Novartis or your infusion center.

Site-of-service optimization. Requesting your infusion at an independent infusion center or physician's office rather than a hospital outpatient department can cut total costs by 30% to 50%. A 2021 study in Osteoporosis International found that office-based zoledronic acid infusion cost an average of $380 less per visit compared to hospital outpatient settings 9.

Pharmacy discount programs. GoodRx, RxAssist, and similar aggregators may list Washington-specific pricing for generic zoledronic acid. Prices through these programs have been reported as low as $350 to $500 for the drug alone.

Medicare Part B. For patients aged 65 and older, zoledronic acid is covered under Medicare Part B (not Part D) because it is physician-administered. After the annual Part B deductible ($257 in 2026), Medicare pays 80%, leaving you responsible for 20% coinsurance. A Medigap plan or Medicaid (for dual-eligibles) can cover that remaining 20%.

Telehealth Prescribing in Washington

Washington state allows telehealth prescribing of zoledronic acid. A physician, nurse practitioner, or physician assistant licensed in Washington can evaluate you via video or audio visit and write a prescription for the drug. The prescription is then filled by a pharmacy or specialty pharmacy, and the actual infusion takes place in person at a clinic or infusion center.

This hybrid model works well for patients in rural parts of Washington. Eastern Washington and the Olympic Peninsula have fewer endocrinologists and rheumatologists per capita than the Seattle-Tacoma metro area. A telehealth evaluation can eliminate the need for a separate in-person visit solely for the prescribing decision, while the infusion itself still requires direct clinical supervision.

Washington's telehealth parity law (RCW 48.43.735) requires commercial insurers to cover telehealth visits at the same rate as in-person visits, which means you should not face a higher copay for the prescribing appointment simply because it occurred over video 10.

Pre-infusion lab work (serum calcium, creatinine, and estimated GFR) can be ordered during the telehealth visit and completed at any local lab. Zoledronic acid is contraindicated in patients with creatinine clearance <35 mL/min, so renal function must be confirmed before each infusion 1.

What to Expect on Infusion Day

Zoledronic acid 5 mg is delivered as a single IV infusion over no fewer than 15 minutes. The infusion itself is straightforward, but about 30% of patients experience an acute-phase reaction (flu-like symptoms including fever, myalgia, and arthralgia) within 24 to 72 hours after the first infusion 3. This reaction is less common with subsequent annual infusions, dropping to approximately 7% by the second year.

Pre-treatment with acetaminophen 650 mg to 1 to 000 mg taken 30 to 60 minutes before the infusion can reduce the severity of the acute-phase reaction. Adequate hydration before and after the infusion is also recommended. Patients should drink at least 500 mL of water in the two hours before the infusion.

Post-infusion monitoring varies by facility. Some centers observe patients for 15 to 30 minutes afterward; others discharge immediately. Your next infusion is scheduled 12 months later for osteoporosis treatment or 24 months later for osteoporosis prevention.

The AACE/ACE 2020 Clinical Practice Guidelines recommend reassessing fracture risk and bone mineral density after three annual infusions to determine whether a bisphosphonate holiday is appropriate 11. Zoledronic acid has the longest skeletal half-life of any bisphosphonate, which supports drug holidays of up to three years in patients who have achieved stable bone density and remain at moderate fracture risk.